These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17537865)

  • 1. X-ray crystal structures of human immunodeficiency virus type 1 protease mutants complexed with atazanavir.
    Klei HE; Kish K; Lin PF; Guo Q; Friborg J; Rose RE; Zhang Y; Goldfarb V; Langley DR; Wittekind M; Sheriff S
    J Virol; 2007 Sep; 81(17):9525-35. PubMed ID: 17537865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
    Muzammil S; Armstrong AA; Kang LW; Jakalian A; Bonneau PR; Schmelmer V; Amzel LM; Freire E
    J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
    Clemente JC; Coman RM; Thiaville MM; Janka LK; Jeung JA; Nukoolkarn S; Govindasamy L; Agbandje-McKenna M; McKenna R; Leelamanit W; Goodenow MM; Dunn BM
    Biochemistry; 2006 May; 45(17):5468-77. PubMed ID: 16634628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of different inhibitors with active-site aspartyl residues of HIV-1 protease and possible relevance to pepsin.
    Sayer JM; Louis JM
    Proteins; 2009 May; 75(3):556-68. PubMed ID: 18951411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
    Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
    J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
    Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
    Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
    Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
    Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
    FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.
    Ala PJ; Huston EE; Klabe RM; McCabe DD; Duke JL; Rizzo CJ; Korant BD; DeLoskey RJ; Lam PY; Hodge CN; Chang CH
    Biochemistry; 1997 Feb; 36(7):1573-80. PubMed ID: 9048541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.
    Mahalingam B; Wang YF; Boross PI; Tozser J; Louis JM; Harrison RW; Weber IT
    Eur J Biochem; 2004 Apr; 271(8):1516-24. PubMed ID: 15066177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M; Bray J; Rezácová P; Sasková K; Brynda J; Pokorná J; Mammano F; Rulísek L; Konvalinka J
    J Mol Biol; 2007 Dec; 374(4):1005-16. PubMed ID: 17977555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials.
    Chen Z; Li Y; Schock HB; Hall D; Chen E; Kuo LC
    J Biol Chem; 1995 Sep; 270(37):21433-6. PubMed ID: 7665551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
    Perryman AL; Lin JH; Andrew McCammon J
    Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs.
    Cheng C; Vedananda S; Wu L; Harbeson S; Braman V; Tung R
    J Mass Spectrom; 2013 Sep; 48(9):1019-31. PubMed ID: 24078243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
    Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
    J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H; Schön A; Freire E
    Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.
    Cihlar T; He GX; Liu X; Chen JM; Hatada M; Swaminathan S; McDermott MJ; Yang ZY; Mulato AS; Chen X; Leavitt SA; Stray KM; Lee WA
    J Mol Biol; 2006 Oct; 363(3):635-47. PubMed ID: 16979654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes.
    Mahalingam B; Louis JM; Hung J; Harrison RW; Weber IT
    Proteins; 2001 Jun; 43(4):455-64. PubMed ID: 11340661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
    Tie Y; Boross PI; Wang YF; Gaddis L; Hussain AK; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
    J Mol Biol; 2004 Apr; 338(2):341-52. PubMed ID: 15066436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs.
    Perryman AL; Lin JH; McCammon JA
    Protein Sci; 2004 Apr; 13(4):1108-23. PubMed ID: 15044738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.